The sarculator stratified prognosis of patients with high-risk soft tissue sarcomas (STS) of extremities and trunk wall treated with perioperative chemotherapy in a randomised controlled trial (RCT).
Sandro Pasquali(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Vittorio Quagliuolo(Humanitas University), Rita De Sanctis(Humanitas University), Angelo Paolo Dei Tos(University of Padua), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandro Comandone(Ospedale Humanitas Gradenigo), Chiara Colombo(The University of Texas MD Anderson Cancer Center), Antonino De Paoli(Centro di Riferimento Oncologico), Giovanni Grignani(Candiolo Cancer Institute), Stefano Bottelli(Fondazione IRCCS Istituto Nazionale dei Tumori), Elena Palassini(Fondazione IRCCS Istituto Nazionale dei Tumori), Piero Picci(Istituto Ortopedico Rizzoli), Antonio López–Pousa(Hospital de Sant Pau), Stefano Ferrari(University of Bergamo), Andrés Poveda(Hospital Quirónsalud Barcelona), Antonio Llombart‐Bosch(Universitat de València), Paolo Verderio(Fondazione IRCCS Istituto Nazionale dei Tumori), Josefina Cruz(Hospital Universitario de Canarias), Javier Martín‐Broto(Hospital Universitario Fundación Jiménez Díaz)
Cited by 5
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k